OBiO Tech(SH:688238)2023-04-26 16:00Financial Performance - The company's revenue for Q1 2023 was CNY 30,791,377, representing a decrease of 57.89% compared to the same period last year[5]. - The net profit attributable to shareholders was -CNY 31,743,281.26, a decline of 363.00% year-over-year[5]. - The basic earnings per share (EPS) was -CNY 0.0644, down 309.77% from the previous year[6]. - The net profit for Q1 2023 was -31,806,061.95 RMB, compared to a net profit of 12,069,474.76 RMB in Q1 2022, indicating a significant decline[25]. - Operating profit for Q1 2023 was a loss of ¥32,492,918.48, compared to a profit of ¥13,478,822.68 in Q1 2022[24]. - The total comprehensive income for Q1 2023 was -31,926,525.95 RMB, compared to 12,069,474.76 RMB in Q1 2022, showing a substantial decrease[25]. Research and Development - R&D expenses totaled CNY 11,269,831.53, an increase of 58.80% compared to the same period last year, accounting for 36.60% of revenue, up 26.89 percentage points[6]. - The company is focused on providing leading-edge, ready-to-use, and cost-effective biological reagent products to enhance R&D efficiency in the life sciences sector[16]. - Research and development expenses increased to CNY 10,186,117.74 in Q1 2023, up 57.5% from CNY 6,476,625.35 in Q1 2022[34]. Cash Flow and Liquidity - The net cash flow from operating activities was -CNY 32,994,071.49, indicating a significant cash outflow[5]. - Operating cash flow for Q1 2023 was -32,994,071.49 RMB, compared to -29,414,344.01 RMB in Q1 2022, reflecting a worsening cash flow situation[27]. - The company’s cash flow from operating activities was significantly negative, indicating challenges in maintaining operational liquidity[27]. - The company reported cash inflows from investment activities of 135,357,049.87 RMB in Q1 2023, with cash outflows of 427,377,366.68 RMB, resulting in a net cash flow from investment activities of -292,020,316.81 RMB[28]. - The company’s cash flow from financing activities in Q1 2023 was 134,792,214.05 RMB, a significant decrease from 1,284,012,398.16 RMB in Q1 2022[28]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,505,295,721.15, a slight increase of 0.61% from the end of the previous year[6]. - Total liabilities as of March 31, 2023, were ¥362,527,460.23, up from ¥318,879,989.48 at the end of 2022, an increase of 13.66%[22]. - The total current liabilities were CNY 186,933,628.19, with a breakdown including accounts payable of CNY 36,536,205.82 and contract liabilities of CNY 19,573,347.75[41]. - The total non-current liabilities amounted to CNY 131,946,361.29, a decrease from CNY 138,339,121.54[41]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,988[12]. - The largest shareholder, Pan Oudong, holds 94,465,800 shares, representing 19.15% of total shares[12]. Investments and Projects - The company has completed the overseas investment project registration for its subsidiary OBiO TECH, INC, with an initial investment of $2.4 million[16]. - The "He Yuan Intelligent Manufacturing Precision Medical Industry Base" opened in Shanghai with a total investment of approximately RMB 1.5 billion, covering an area of 77,000 square meters[18]. - As of March 31, 2023, over RMB 700 million has been invested in the first phase of the medical industry base project, which is expected to officially commence production in the second half of the year[18]. - The company established a joint venture with Shanghai Li Ji Biotechnology Co., Ltd. and Shanghai Li Ji Pharmaceutical Technology Co., Ltd., holding a 60% stake[16]. - The company participated as a limited partner in the establishment of the Shanghai Hongsheng Houde Private Equity Fund, which has completed registration and obtained the private fund filing certificate[17]. Workforce - The company has increased its workforce to 648 employees as of the end of the first quarter of 2023[16].